Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine

Clinical and Vaccine Immunology

Volumn 14, Issue 4, 2007, Pages 426-434

  Schmitt, Heinz J ^a   Maechler, Gudrun ^b,c   Habermehl, Pirmin ^a   Knuf, Markus ^a   Saenger, Roland ^b,c   Begg, Norman ^b   Boutriau, Dominique ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCAL SEROGROUP C TETANUS TOXOID PLUS DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B VIRUS INACTIVATED POLIOVIRUS VACCINE; MENCEVAX; MENINGOCOCCAL POLYSACCHARIDE C PLUS DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B VIRUS INACTIVATED POLIOVIRUS PLUS HAEMOPHILUS INFLUENZA TYPE B VACCINE; MENINGOCOCCAL SEROGROUP C CRM 197 PLUS DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B VIRUS INACTIVATED POLIOVIRUS PLUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCAL SEROGROUP C TETANUS TOXOID PLUS DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B VIRUS INACTIVATED POLIOVIRUS PLUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; POLYRIBOSYLRIBITOLPHOSPHATE ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANOREXIA; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG CONJUGATION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; INFLUENZA; IRRITABILITY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PAIN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN REDNESS; SWELLING; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, BACTERIAL; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE;

EID: 34248383229     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00377-06     Document Type: Article

References (24)

1. Anderson, M. S., M. P. Glodé, and A. L. Smith. 1998. Meningococcal disease, p. 1143-1156. In R. D. Feigin and J. D. Cherry (ed.), Textbook of pediatric infectious diseases. W. B. Saunders Company, Philadelphia, PA.
2. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
3. Arístegui, J., R. Dal-Ré, J. Díez-Delgado, J. Mares, J. M. Casanovas, P. Garcia-Corbeira, E. De Frutos, D. Van Esso, J. Verdaguer, J. De la Flor, F. Moraga, R. Boceta, and J. A. Garcia-Martinez. 2003. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21:3593-3600.
4. Australian Meningococcal Surveillance Programme. 2002. Annual report of the Australian Meningococcal Surveillance Programme, 2001. Commun. Dis. Intell. 26:407-418.
5. Böhm, O., and R. von Kries. 1997. Are Hib boosters redundant? Lancet 350:67.
6. Borrow, R., D. Goldblatt, A. Finn, J. Southern, L. Ashton, N. Andrews, G. Lal, C. Riley, R. Rahim, K. Cartwright, G. Allan, and E. Miller. 2003. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect. Immun. 71:5549-5555.
7. Jodar, L., I. M. Feavers, D. Salisbury, and D. M. Granoff. 2002. Development of vaccines against meningococcal disease. Lancet 359:1499-1508.
8. Kitchin, N. R., J. Southern, R. Morris, F. Hemme, S. Thomas, M. W. Watson, K. Cartwright, and E. Miller. 2007. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child. 92:11-16.
9. Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. Devi, C. E. Frasch, J. C. Huang, P. Kriz-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. Peeters, S. Quataert, J. Y. Ta, and G. M. Carlone. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
10. Miller, E., D. Salisbury, and M. Ramsay. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20:S58-S67.
11. Netherlands Reference Laboratory for Bacterial Meningitis. 2003. Bacterial meningitis in The Netherlands: annual report. Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center of the University of Amsterdam, and National Institute of Public Health and the Environment, Amsterdam, The Netherlands.
12. Noah, N., and B. Henderson. 2002. Surveillance of bacterial meningitis in Europe, 1999/2000, abridged version. The European Bacterial Meningitis Surveillance Project, PHLS Communicable Disease Surveillance Centre, London, United Kingdom. www.hpa.org.uk/hpa/inter/m_surveillance9900.pdf.
13. Peltola, H. 1998. Meningococcal vaccines. Current status and future possibilities. Drugs 55:347-366.
14. Ramsay, M. E., J. McVernon, N. J. Andrews, P. T. Heath, and M. P. Slack. 2003. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 188:481-485.
15. Richmond, P., R. Borrow, E. Miller, S. Clark, F. Sadler, A. Fox, N. Begg, R. Morris, and K. Cartwright. 1999. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179:1569-1572.
16. Richmond, P., R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, K. Cartwright, and E. Miller. 2001. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
17. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
18. Schmitt, H. J., F. Zepp, S. Müschenborn, G. Sumenicht, A. Schuind, K. Beutel, M. Knuf, H. L. Bock, H. Bogaerts, and R. Clemens. 1998. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and booster immunizations. Eur. J. Pediatr. 157:208-214.
19. Snape, M. D., D. F. Kelly, B. Green, E. R. Moxon, R. Borrow, and A. J. Pollard. 2005. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide- protein conjugate vaccine. Pediatr. Infect. Dis. J. 24:128-131.
20. Steinhoff, M., and D. Goldblatt. 2003. Conjugate Hib vaccines. Lancet 361:360-361.
21. Tejedor, J. C., M. Moro, J. Ruiz-Contreras, J. Castro, J. A. Gómez-Campderá, M. L. Navarro, J. M. Merino, A. Martin-Ancel, J. Roca, M. Garcia-del-Ri, A. Jurado, F. J. Diez-Delgado, F. Omenaca, J. Garcia-Sicilia, R. Bocetas, P. Garcia-Corbeira, A. Collard, D. Boutriau, L. Schuerman, and J. M. Jacquet. 2007. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis coadministered with a diphtheria-tetanus- acellular pertusis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr. Infect. Dis. J. 26:1-7.
22. Tichmann-Schumann, I., P. Soemantri, U. Behre, J. Disselhoff, H. Mahler, G. Maechler, R. Sanger, J. M. Jacquet, and L. Schuerman. 2005. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three- component acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 24:70-77.
23. Trotter, C. L., N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367.
24. Van Loock, F., G. Ducoffre, and F. Carion. 2001. Meningokokkeninfecties: staan we voor een nieuwe epidemie? Epidemiol. Bull. Vlaamse Gemeenschap 36:4-7.